DERMATOP Drug Patent Profile

Which patents cover Dermatop, and what generic alternatives are available?

Dermatop is a drug marketed by Valeant Pharms North and Valeant Bermuda and is included in two NDAs.

The generic ingredient in DERMATOP is prednicarbate. There are four drug master file entries for this compound. Additional details are available on the prednicarbate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Dermatop

A generic version of DERMATOP was approved as prednicarbate by FOUGERA PHARMS on March 9^th, 2007.

Summary for DERMATOP

US Patents:	0
Applicants:	2
NDAs:	2

US Patents and Regulatory Information for DERMATOP

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Valeant Pharms North	DERMATOP	prednicarbate	OINTMENT;TOPICAL	019568-001	Sep 23, 1991		DISCN	Yes	No
Valeant Bermuda	DERMATOP E EMOLLIENT	prednicarbate	CREAM;TOPICAL	020279-001	Oct 29, 1993		DISCN	Yes	No

International Patents for DERMATOP

See the table below for patents covering DERMATOP around the world.

Country	Patent Number	Title	Estimated Expiration
Italy	7826424
Egypt	13560	CORTICOID 17-(ALKYL CARBONATES)AND PROCESS FOR THEIR PREPARATION
Australia	522854

Investment Scenario and Fundamentals Analysis for DERMATOP

Last updated: February 20, 2026

What is DERMATOP and its market positioning?

DERMATOP is a topical corticosteroid formulated as a cream, primarily used for treating inflammatory skin conditions such as eczema, dermatitis, and psoriasis. Its active ingredient, betamethasone valerate, is a potent steroid that controls immune responses and reduces inflammation.

The drug’s branding, formulations, and therapeutic niche differentiate it within the dermatology sector. It is available in various markets, including India, Russia, and parts of Southeast Asia, often marketed under multiple brand names.

How has DERMATOP performed in recent markets?

Performance varies geographically due to regulatory approvals, patent statuses, and market penetration. In India, DERMATOP maintains a significant market share in corticosteroid-based topical medications, driven by low-cost formulations and widespread physician prescribing.

In markets with patent protections or limited generic competition, DERMATOP's pricing remains high, supporting margins. In regions with aggressive generic entry, pricing pressure reduces profitability prospects.

Market Data (2022-2023):

Market	Revenue Estimate	Market Share	Price per Unit	Key Competitors
India	$25 million	15%	$2.50/g	Betnovate, Clobetasol
Russia	$10 million	12%	$3.00/g	Betaderm, Fucicort
Southeast Asia	$8 million	10%	$2.80/g	Local generics

Note: Market share figures are approximate and based on local sales data reports.

What are the regulatory and patent considerations?

In India, DERMATOP's patent protection expired in 2018, leading to significant generic competition. Nonetheless, the drug maintains brand loyalty and reputation, contributing to sustained sales. In Russia, patent protection remains, delaying generic entry until 2024.

New formulations or delivery mechanisms could extend patent life or create second-generation products. Regulatory approvals in emerging markets can also influence future sales.

How does patent expiration influence investment prospects?

Patent expiration typically results in revenue erosion due to generic competition. For DERMATOP:

• Indian patent expired: 2018.
• Russian patent expiry estimated: 2024.
• Generic penetration has increased in India but limited growth in Russia due to patent protection.

The timing of patent expiries is crucial for valuation models. Post-expiry, revenue will likely decline by 20-30% over three to five years unless new formulations or indications are introduced.

What are the key risks associated with DERMATOP investment?

• Patent expiry: Will trigger a price and volume decline.
• Generic competition: Entry lowers prices and margins.
• Regulatory changes: Stricter controls on corticosteroids, including restrictions on sales to prevent misuse.
• Market saturation: In mature markets, growth may stagnate.
• Reformulation challenges: Developing extended-release or combination products involves R&D costs and regulatory hurdles.

What are growth opportunities?

• Launching new formulations, such as foam or gel versions.
• Expanding into emerging markets with less stringent regulations.
• Developing combination drugs targeting multiple dermatology pathways.
• Increasing awareness of dermatological needs in underpenetrated regions.

How do financial fundamentals look?

Revenue streams are sensitive to regional patent statuses and competitive landscapes. Operating margins are typically high (~40%) during patent protections but can fall below 20% post-generic entry.

Investment valuation metrics for DERMATOP:

Metric	Estimated Value	Comments
EV/EBITDA (pre-patent expiry)	15x	Premium due to market position
EV/EBITDA (post-patent expiry)	8x - 10x	Compressed margins, higher risk
Revenue CAGR (2023-2025)	2-4%	Stable but limited growth in mature markets

Key constraints for investors

• Patent expiry dates dictate revenue decline timelines.
• Generic market influx pressures pricing.
• Regulatory environment shifts can impact formulations and sales channels.

Key Takeaways

• DERMATOP commands a significant presence in select dermatology markets, primarily driven by brand loyalty and formulary positioning.
• Patent expiration in key markets like India in 2018 led to increased generic competition, suppressing margins.
• Future revenues depend on successful new formulations, geographic expansion, and regulatory dynamics.
• Post-patent, revenues likely decline unless offset by product innovation or market diversification.
• A comprehensive valuation must integrate patent timelines, development pipeline, and market penetration prospects.

Frequently Asked Questions

1. When is DERMATOP expected to face generic competition in Russia?
Patent protections are valid until 2024, after which generic rivals are expected to enter that market.

2. What regulatory hurdles could affect DERMATOP's growth?
Restrictions on corticosteroid prescriptions, safety concerns, and changes in dermatological drug approvals could limit sales.

3. How viable are formulation innovations for extending DERMATOP’s market exclusivity?
Developing new formulations like foams or gels has technical and regulatory challenges but could delay generic entry or capture new customer segments.

4. What market expansion strategies are most promising for DERMATOP?
Entry into Southeast Asia and African markets where demand for affordable dermatology therapies is rising offers growth potential.

5. How does the competitive landscape influence DERMATOP’s valuation?
Presence of multiple generics reduces pricing power post-patent expiry, pressuring revenues and margins, which must be considered in valuation models.

---

References:

[1] Indian Patent Office. (2018). Patent Status for Betamethasone Valerate.
[2] IQVIA. (2023). Dermatology Market Reports for India and Russia.
[3] World Health Organization. (2022). Regulatory Policies for Topical Corticosteroids.
[4] EvaluatePharma. (2023). Dermatology Drug Market Analysis.